Compare iShares Global Clean Energy ETF (ICLN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.22 (market cap $2.27B), while Zimmer Biomet Holdings Inc trades at $89.01 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7.5× iShares Global Clean Energy ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ICLN | ZBH | |
|---|---|---|
Market Cap | $2.27B | $16.95B |
Volume | 6,845,064 | 2,505,240 |
52-Week High | $23.75 | $103.98 |
52-Week Low | $15.78 | $79.58 |
Typical Hold Time | 87 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.17, down 0.81% with bearish technical signals from moving averages. The ETF shows neutral momentum oscillators but faces significant volatility compared to traditional energy peers. Recent news highlights ICLN's 57.2% maximum drawdown and higher expense ratio of 0.38% versus fossil fuel ETFs, though geopolitical tensions are driving renewed interest in renewable energy infrastructure.
The clean energy sector faces competitive pressure from higher-yielding traditional energy ETFs, but long-term growth prospects remain supported by global energy transition trends. Key risks include expense ratio disadvantages and sector volatility, while potential catalysts include increased renewable adoption driven by geopolitical and environmental factors.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
